Weil is advising Sanofi in its acquisition of Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemicmastocytosis (SM), a rare immunological disease, and other KIT-driven diseases. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions.

The Weil team is led by Mergers & Acquisitions partners Michael J. Aiello and Sachin Kohli and includes associates Stephanie Peterson, Alan Chan, Ragan Minor, Rae Kong and Sidy Traore; Tax Head Joseph Pari, partner Graham Magill and associate Madeline Joerg; Antitrust partners John Scribner and Neil Rigby as well as associates Lucy Peckham, Kathryn Graham and Michael Geisler; Technology & IP Transactions Head Charan Sandhu, partner Kane Wishart, counsel Phil Grudzina and associates Jeeyoon Chung, Sabrina Chishti, Taya Bokert and Sarah Schwarz; U.S. Privacy & Cybersecurity Head Olivia Greer and associates David Merck, Taylor Peterson and Kristen Pavlounis; Banking & Finance Co-Head Courtney Marcus and associate Keiko Quinones-Osumi; Labor & Employment partner Rebecca Sivitz and associate Heylee Bernstein; Executive Compensation & Benefits Head Paul Wessel and associates Nate Gross and Maddie Bober; Regulatory Transactions partners Shawn Cooley, John O’Loughlin, Timothy Welch and Matthew Morton and associates Christina Carone, SiSi Liu and Graham McHenry; Capital Markets partner Barbra Broudy and associate Federica Marini; and Real Estate attorney Leslie Smith and associates Ilana Bier and Jules Bienenfeld.